Stock Rich List
#804 on the corporate holders of 809 holders

ARCH Venture Partners IX, L.P.

10% owner at Vir Biotechnology; 10% owner at Lyell Immunopharma; 10% owner at Boundless Bio.

$50.7M
in disclosed stock, −$1.6M (−3.06%) today
Market closed. Prices as of Nov 19, 4:04 PM ET
Rank
804th of 809
Companies held
1
Largest holding
VIR, 100.0% of total
Latest SEC filing
Jul 1, 2026
Listed but not counted
$71.3M

What the $50.7M is made of

Holdings counted

All filings on SEC.gov
CompanyHow heldSharesPriceValueShare of totalReported
Vir Biotechnology VIR
Common Stock
Indirectly (see filing footnote)5,626,008$8.87$49.9M98.4%Form 4, Sep 6, 2022
Vir Biotechnology VIR
Common Stock
Indirectly (see filing footnote)61,160$8.87$542K1.1%Form 4, Sep 6, 2022
Vir Biotechnology VIR
Common Stock
Directly30,570$8.87$271K0.5%Form 4, Sep 6, 2022

Share counts are the amounts ARCH Venture Partners IX, L.P. reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.

Reported but not counted

These shares appear on ARCH Venture Partners IX, L.P.'s filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.

CompanyHow heldSharesPriceValueShare of totalReported
Vir Biotechnology VIR
Common Stock
Through ARCH Venture Fund IX, L.P.
Held by a company or fund the insider manages
5,865,567$8.87$52.0M—Form 4, Sep 2, 2022
Lyell Immunopharma LYEL
Common Stock
Through ARCH Venture Fund IX, L.P.
Held by a company or fund the insider manages
910,317$13.58$12.4M—Form 4, Jul 25, 2025
Boundless Bio BOLD
Common Stock
Through AVP X Overage LP
Held by a company or fund the insider manages
1,181,766$2.38$2.8M—Form 4, Jul 1, 2026
Boundless Bio BOLD
Common Stock
Through ARCH Venture Fund IX Overage, L.P.
Held by a company or fund the insider manages
828,570$2.38$2.0M—Form 4, Jul 1, 2026
Boundless Bio BOLD
Common Stock
Through ARCH Venture Fund IX, L.P.
Held by a company or fund the insider manages
683,759$2.38$1.6M—Form 4, Jul 1, 2026
Vir Biotechnology VIR
Common Stock
Through ARCH Venture Fund IX Overage, L.P.
Held by a company or fund the insider manages
57,912$8.87$514K—Form 4, Sep 2, 2022

Open-market trades, last 12 months

DateTradeCompanySharesPriceValueFiling
Jul 1, 2026SoldBOLD16,000$2.49$40KView

Nearby on the list

Full list
Nearby ranks
RankNameStock holdingsToday
801Insight Satellite Co-Invest, L.P.
10% owner, HawkEye 360
$51.0M−$819K (−1.58%)
802MSD Partners, L.P.
Director, Hayward Holdings
$51.0M−$1.1M (−2.04%)
803Champion River Ventures Ltd
10% owner, Niagen Bioscience
$50.9M−$1.9M (−3.61%)
804ARCH Venture Partners IX, L.P.
10% owner, Vir Biotechnology
$50.7M−$1.6M (−3.06%)
805Summer Road LLC
10% owner, Ocular Therapeutix
$50.3M−$687K (−1.35%)
806OCM Growth Holdings LLC
10% owner, Runway Growth Finance
$50.3M−$994K (−1.94%)
807Regal Planet Ltd
10% owner, CURRENC Group
$50.3M−$1.3M (−2.60%)

Other Vir Biotechnology insiders

All VIR insiders

Questions

How much stock does ARCH Venture Partners IX, L.P. own?

ARCH Venture Partners IX, L.P. holds $50,716,336 in listed stock based on SEC filings and current prices, mostly Vir Biotechnology (VIR). That ranks 804th on the Stock Rich List.

Is this ARCH Venture Partners IX, L.P.'s net worth?

No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.

When did ARCH Venture Partners IX, L.P. last buy or sell stock?

The most recent open-market trade on file is a sale of 16,000 BOLD shares on Jul 1, 2026 at $2.49.

Files jointly with Keith Crandell, Robert Nelsen, SEC filer 1219043.